Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study.

Sparano, Joseph A; Makhson, Anatoly N; Semiglazov, Vladimir F; Tjulandin, Sergei A; Balashova, Olga I; Bondarenko, Igor N; Bogdanova, Natalia V; Manikhas, George M; Oliynychenko, Gennadiy P; Chatikhine, Valery A; Zhuang, Sen H; Xiu, Liang; Yuan, Zhilong; Rackoff, Wayne R

Sparano, Joseph A; Makhson, Anatoly N; Semiglazov, Vladimir F; Tjulandin, Sergei A; Balashova, Olga I; Bondarenko, Igor N; Bogdanova, Natalia V; Manikhas, George M; Oliynychenko, Gennadiy P; Chatikhine, Valery A; Zhuang, Sen H; Xiu, Liang; Yuan, Zhilong; Rackoff, Wayne R.

Affiliation

Sparano JA; Montefiore-Einstein Cancer Center, 1825 Eastchester Rd, Bronx, NY 10461, USA. jsparano@montefiore.org

J Clin Oncol ; 27(27): 4522-9, 2009 Sep 20.

Article in En | MEDLINE | ID: mdl-19687336

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Polyethylene Glycols / Breast Neoplasms / Doxorubicin / Taxoids / Antineoplastic Agents Type of study: Clinical_trials / Guideline Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: J Clin Oncol Year: 2009 Document type: Article Affiliation country: Country of publication:

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google